|
18.03.24 |
GNW-Adhoc: Idorsia and Viatris successfully close the transaction for the global research and development collaboration |
|
28.02.24 |
GNW-Adhoc: Idorsia and Viatris enter into a significant global research and development collaboration |
|
28.02.24 |
Idorsia and Viatris enter into a significant global research and development collaboration |
|
10.01.24 |
GNW-Adhoc: Idorsia presents at the J.P. Morgan Healthcare Conference - Adapting Idorsia for sustainable value creation |
|
03.11.23 |
GNW-Adhoc: New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023 |
|
03.11.23 |
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023 |
|
24.10.23 |
GNW-Adhoc: Idorsia gibt Finanzergebnisse für die ersten neun Monate 2023 bekannt - Anpassung des Unternehmens zur Schaffung von nachhaltigem Wert |
|
23.10.23 |
GNW-Adhoc: Idorsia is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023 |
|
17.10.23 |
GNW-Adhoc: Invitation to Idorsia's Nine-Month 2023 Financial Reporting webcast and conference call |
|
23.05.22 |
Aktien, Märkte, Branchen in Zahlen - Europas Top Biotech-Aktien |
|
23.05.22 |
News aus dem Börse Express PDF vom 23.05.2022 (Spiel, Satz, Fragezeichen - Zahlen von betathome.com, Marinomed - ams Osram, Erste Group, OMV, SBO, vienna Insurance Group, Wienerberger - Europäische Biotechbranche - Die Einbahnstraße Aktienmarkt ...) |
|
08.02.22 |
Idorsia gibt Finanzergebnisse für 2021 bekannt – 2022 wird ein Jahr der Transformation – Nachhaltige Rentabilität soll 2025 erreicht werden |
|
26.01.22 |
Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada |
|
10.01.22 |
Idorsia presents at the 40th J.P. Morgan Healthcare Conference – Ready for first product launches – QUVIVIQ (daridorexant) approved by the US FDA |
|
10.01.22 |
Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia |